GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 71.84B |
| Revenue (ttm) | 32.17B |
| Net Income (ttm) | 5.49B |
| Shares Out | 4.02B |
| EPS (ttm) | 1.33 |
| PE Ratio | 13.46 |
| Forward PE | 9.99 |
| Dividend | 0.61 (3.41%) |
| Ex-Dividend Date | Nov 13, 2025 |
| Volume | 8,669,427 |
| Average Volume | 9,206,041 |
| Open | 1,756.50 |
| Previous Close | 1,760.50 |
| Day's Range | 1,753.00 - 1,788.00 |
| 52-Week Range | 1,242.50 - 1,830.00 |
| Beta | 0.23 |
| RSI | 60.76 |
| Earnings Date | Oct 29, 2025 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial StatementsNews
AnaptysBio Buckles After Trading Legal Barbs With Pharma Giant GSK
AnaptysBio stock buckled Friday after the biotech company and GSK filed competing lawsuits against one another over a licensing deal.
Why GSK (GSK) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AnaptysBio (ANAB) Faces Legal Battle with GSK's Subsidiary Over Cancer Drug Agreement
AnaptysBio (ANAB) Faces Legal Battle with GSK's Subsidiary Over Cancer Drug Agreement
AnaptysBio (ANAB) Shares Plunge Amid Legal Battle with GSK
AnaptysBio (ANAB) Shares Plunge Amid Legal Battle with GSK
AnaptysBio shares tumble after legal fight with GSK over cancer drug license
Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's GSK , filed lawsuits against each other, with both claiming a breach in a par...
GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties
GSK plc (NYSE: GSK) subsidiary, Tesaro Inc ., has initiated litigation against AnaptysBio, Inc. (NASDAQ: ANAB) in the Delaware Chancery Court. ANAB is encountering selling pressure. Get the scoop he...
GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties
GSK plc (NYSE: GSK) subsidiary, Tesaro Inc., has initiated litigation against AnaptysBio, Inc. (NASDAQ: ANAB) in the Delaware Chancery Court.
AnaptysBio drops as litigation with GSK unit risks cancer therapy deal
GSK, AnaptysBio Sue Each Other Over Cancer Drug License
The companies accuse one another of breaching a licensing agreement for Jemperli, a drug used to treat some forms of endometrial cancer.
GSK Faces Legal Challenge Over Alleged Interference with AnaptysBio Collaboration
GSK Faces Legal Challenge Over Alleged Interference with AnaptysBio Collaboration
TESARO Pursues Litigation Against AnaptysBio For Alleged Material Breach Of Jemperli Agreement
(RTTNews) - GSK plc.'s (GSK) subsidiary TESARO Inc. has commenced litigation against AnaptysBio Inc. (ANAB), contending that AnaptysBio has materially violated the terms of their licensing agreement r...
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a ...
GSK's Tesaro Sues AnaptysBio Over Jemperli License Dispute
(RTTNews) - GSK plc (GSK), a biopharmaceutical company's subsidiary Tesaro, Inc. (TSRO), on Friday announced that it has filed litigation in the Delaware Chancery Court against AnaptysBio, Inc. (ANAB)...
GSK (GSK) Pursues Legal Action Against AnaptysBio Over License Dispute
GSK (GSK) Pursues Legal Action Against AnaptysBio Over License Dispute
GSK (GSK) Partners with LTZ for Innovative Cancer Treatments
GSK (GSK) Partners with LTZ for Innovative Cancer Treatments
GSK inks deal with LTZ Therapeutics to develop hematologic cancer therapies
GSK partners with LTZ Therapeutics to develop novel myeloid cell engager treatments for cancer using innovative immuno-oncology technology. Read more here.
GSK (GSK): CDC Updates Vaccination and Autism Information
GSK (GSK): CDC Updates Vaccination and Autism Information
GSK plc (GSK) Presents at Jefferies London Healthcare Conference 2025 Transcript
GSK Completes Acquisition of BREXAFEMME NDA for U.S. Market Relaunch
GSK Completes Acquisition of BREXAFEMME NDA for U.S. Market Relaunch
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are rushing to boost U.S. manufacturing and inventory as the Trump administration weighs a 100% tariff on imported branded and patented drugs.
UK officials ‘working night and day to resolve NHS drug pricing row’
Patrick Vallance says government trying to rebuild relations with pharma industry as he outlines life sciences ambition The UK science minister has said officials are “working day and night” trying to...
The Best Healthcare Stock to Hold in Uncertain Times
Looking for a cheap, safe healthcare stock to buy? Take two shares of GSK and call me in the morning.
Kahn Brothers' Strategic Moves: GSK PLC Sees a -3.08% Impact
Kahn Brothers' Strategic Moves: GSK PLC Sees a -3.08% Impact
GSK CEO among candidates considered for Diageo leadership: FT
Diageo (DEO) has weighed multiple candidates including outgoing GSK (GSK) CEO Emma Walmsley for its leadership role as CEO search frustrates investors. Read more here.
GSK (GSK) Highlights Liver Disease Research Developments at AASLD 2025
GSK (GSK) Highlights Liver Disease Research Developments at AASLD 2025